Background: Approximately 1% to 3% of all gastric cancers are associated with families exhibiting an autosomal dominant pattern of susceptibility. E-cadherin (CDH1) truncating mutations have been shown to be present in approximately 30% of families with hereditary diffuse gastric cancer (HDGC) and are associated with a significantly increased risk of gastric cancer and lobular breast cancer. Methods: Individuals from a large kindred with HDGC who were identified to have a CDH1 mutation prospectively underwent comprehensive screening with stool occult blood testing, standard upper gastrointestinal endoscopy with random gastric biopsies, high-magnification endoscopy with random gastric biopsies, endoscopic ultrasonography, CT, and PET scans to evaluate the stomach for occult cancer. Subsequently, they each underwent total gastrectomy with D-2 node dissection and Roux-en-y esophagojejunostomy. The stomach and resected lymph nodes were evaluated pathologically. Results: Six patients were identified as CDH1 carriers from a single family. There were 2 men and 4 women. The mean age was 54 years (range, 51-57 years). No patient had any signs or symptoms of gastric cancer. Exhaustive preoperative stomach evaluation was normal in each case, and the stomach and adjacent lymph nodes appeared normal at surgery. However, each patient (6 of 6, 100%) was found to have multiple foci of T1 invasive diffuse gastric adenocarcinoma (pure signet-ring cell type). No patient had lymph node or distant metastases. Each was staged as T1N0M0. Each patient recovered uneventfully without morbidity or mortality. Conclusions: CDH1 mutations in individuals from families with HDGC are associated with gastric cancer in a highly penetrant fashion. CDH1 mutations are an indication for total gastrectomy in these patients. This mutation will identify patients with cancer before other detectable symptoms or signs of the disease. Surg 2007;245: 873-879) From the Departments of *Surgery, †Gastroenterology, ‡Radiology, §Pathology, ¶Medicine, and #Genetics, Stanford University School of Medicine,
G astric cancer is second in cancer deaths worldwide. 1 The dramatic decrease in adenocarcinoma of the stomach in the United States during the past 70 years has occurred in the "intestinal" form of the disease, which is associated with achlorhydria, intestinal metaplasia, and Helicobacter pylori infections. 2 However, there has been a relative increase in proximal gastric cancers, gastroesophageal cancers, and distal esophageal adenocarcinomas, particularly those associated with Barrett's epithelium. The diffuse type of gastric cancer is less common and has not decreased in incidence. It is characterized by a signet-ring cell infiltrate, is multifocal and associated with a familial predisposition. [3] [4] [5] [6] Diet and infection with H. pylori are the predominant environmental risk factors for gastric cancer, 7, 8 but familial aggregation in a variable, but significant, proportion of cases suggests the importance of genetic predisposition. 2, 9 Familial gastric cancer is a disease with an autosomal dominant inheritance in which gastric cancer develops at a young age. About 10% of the cases of gastric cancer, both the diffuse and intestinal type, show familial clustering. 2, 9 The first clear evidence for a gastric cancer susceptibility genetic locus was the identification in 1998 of germline inactivating (truncating) mutations in the gene encoding E-cadherin, called CDH1, in 3 large Maori families from New Zealand with diffuse early-onset gastric cancer. 10 The pattern of inheritance was consistent with an autosomal dominant susceptibility gene with high penetrance. Hereditary diffuse gastric cancer (HDGC) caused by germline mutations in CDH1 has subsequently been shown to occur in a number of families with different ethnic backgrounds, including European, African American, Pakistani, Japanese, Korean, and others. [11] [12] [13] [14] [15] [16] [17] CDH1 is localized on chromosome 16q22.1 14 and encodes for a protein that comprises 5 extracellular cadherin repeats, a transmembrane region, and a highly conserved cytoplasmic tail. It functions as a calciumdependent cell-cell adhesion glycoprotein. It is hypothesized that CDH1 acts as a tumor suppressor gene, and loss of function through inactivating mutations or promoter methylation leads to development and progression of cancer by lack of inhibition of cell adhesion. 5, 18, 19 Its inhibition increases cell proliferation, invasion, and metastases. Besides HDGC, CDH1 mutations are associated with an increased incidence of lobular carcinoma of the breast and, possibly, colorectal carcinoma and prostate cancer. 13, 20, 21 Missense mutations of CDH1 (unlike truncating ones) are not clearly associated with these hereditary cancer risks. 22 The lifetime cancer-specific risks associated with germline CDH1 mutations are thought to be Ͼ70% for gastric cancer and up to 40% for lobular breast cancer in women. 17 In 3 previous publications, a few apparently asymptomatic patients from kindreds with CDH1 mutations and HDGC underwent prophylactic gastrectomy based on detection of an inherited CDH1 mutation. 1, 23, 24 Most had been shown to have diffuse (signet-ring cell type) gastric cancer on pathologic analysis. Therefore, we decided to perform a prospective study of the role of total gastrectomy and D-2 lymph node dissection in patient kindreds with HDGC and CDH1 gene mutations, including comprehensive preoperative screening procedures. We report out initial experience with 6 patients from one large kindred who underwent total gastrectomy for a CDH1 mutation without any evidence of gastric cancer on detailed preoperative imaging studies, including standard upper gastrointestinal endoscopy with multiple random biopsies, high-magnification endoscopy with methylene blue chromoendoscopy, endoscopic ultrasound, multiple blind gastric biopsies, computed tomography (CT), and positron emission tomography (PET) scan with fluorodeoxyglucose. Each was found to have multiple sites of invasive diffuse signet-ring cell type gastric adenocarcinoma without lymph node metastases.
MATERIALS AND METHODS
The criteria for the definition of HDGC used in this study include families with 1) 2 or more pathologically documented cases of diffuse gastric cancer in first-or seconddegree relatives, with at least one diagnosed before the age of 50 years, and 2) 3 or more pathologically documented cases of diffuse gastric cancer in first-or second-degree relatives of any age. 2 Once the family was identified, the proband had genomic DNA extracted and purified as previously described. Screening for CDH1 germline mutations was done by denaturing high-performance liquid chromatography and automated DNA sequencing. 1 Affected individuals who inherited the germline mutation and nonaffected individuals are shown in the pedigree ( Fig. 1 ). Of the 14 living family members identified with CDH1 mutations, 8 were seen at Stanford for genetic counseling, and 6 entered onto our IRB approved protocol for comprehensive screening and prophylactic gastrectomy.
All individuals who entered our protocol had a confirmed 1003C ϾT (R335X) exon 7 CDH1 mutation (Fig. 2) , and underwent complete history and physical examination, Individual mutation testing results for the codon 1003 CDH1 mutation are indicated by a ؉ or Ϫ. Individuals affected with GC are shaded. The 6 who underwent prophylactic gastrectomy on the current study are numbered 1 to 6. Five other individuals who have had prophylactic gastrectomies are labeled a to e. Individual c had the procedure prior to the availability of genetic testing but was ultimately found not to have inherited a CDH1 mutation.
FIGURE 2.
The mutation in this kindred is located in the central region of the E-cadherin gene that codes for the extracellular cadherin domains of the protein that contain calcium binding motifs important in the adhesion process. The C-ϾT transition in exon 7 of nucleotide 1003 resulted in a premature stop codon (R335X), thereby producing truncated peptides lacking the transmembrane and cytoplasmic ␤-catenin binding domains essential for tight cell-cell adhesion. Black area indicates truncated portion of peptide. N, N-terminus; C, C-terminus; S, signal peptide; PRE, precursor sequence; TM, transmembrane domain; CP, cytoplasmic domain.
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Annals of Surgery • Volume 245, Number 6, June 2007 standard blood hematology and chemistry studies, high resolution multiphasic abdominal CT, PET scan, standard endoscopy, high-magnification endoscopy with methylene blue chromoscopy, multiple (Ͼ6) random gastric biopsies, and endoscopic ultrasonography. 25 Women also underwent complete breast examination, mammogram and bilateral magnetic resonance imaging (MRI) of the breast on a screening protocol for women at high genetic risk of breast cancer. 26 After informed consent irregardless of the results of the above studies, each underwent total gastrectomy, omentectomy, D-2 lymph node dissection, and Roux-en-Y esophagojejunostomy. The Roux-en-Y esophagojejunostomy did not include a pouch. The end of the esophagus was anastomosed to the side of the jejunum with an EEA stapler. Pathologic analyses of the resected specimens were as previously described. 1 Briefly, the entire stomach was fixed in formaldehyde, serially sectioned, embedded in paraffin, and examined microscopically. On postoperative day 5, each patient underwent a gastrograffin upper gastrointestinal series to examine the esophagojejunostomy and then was advanced from a clear liquid to a postgastrectomy diet as tolerated. Follow-up data about tumor status, eating ability, endurance, weight, and quality of life are provided.
RESULTS
Fourteen living patients were identified in one large kindred who had a truncating germline mutation of CDH1 and met the criteria for HDGC. Two other HDGC families have been described in the literature with an identical mutation at codon 1003, but we have previously shown by haplotype analysis using microsatellite markers that this is not a founder mutation, and that our family was not related to the other 2 ͓1͔. Six CDH1 carriers in this family chose to pursue screening and prophylactic gastrectomy on our protocol. There were 2 men and 4 women. The mean age was 54 years. The youngest was 51 years, while the oldest was 57 years. No patient had any symptoms related to the stomach, occult blood in the stool by guaiac test, or any other symptoms. Each had a normal CT scan of the abdomen and a normal PET scan. Each had a normal upper GI endoscopy and endoscopic ultrasound of the stomach, high-magnification endoscopy with methylene blue chromoscopy. Multiple random gastric biopsies from multiple sites within the stomach of each patient did not show any evidence of gastric cancer.
Each patient underwent total gastrectomy with D-2 lymph node dissection and Roux-en-Y esophagojejunostomy without complication or mortality. Each was done as an open procedure with postoperative epidural pain medication. No patient received a blood transfusion. The average length of postoperative stay was 7 days (range, 6 -10 days). Each patient had a normal swallowing evaluation of the esophagojejunostomy on postoperative day 5. Each patient was discharged on a 6 small feed postgastrectomy diet. The pathologic analysis of each surgical specimen showed multifocal invasive diffuse (signet-ring cell) adenocarcinoma of the stomach that was limited to the mucosa (T1) (Fig. 3) . In situ carcinoma with signet-ring cell histology was also identified in 2 patients. The non-neoplastic mucosa exhibited mild foveolar hyperplasia and tufting, as previously described. No intestinal metaplasia was detected. 19 Immunohistochemistry for E-cadherin protein demonstrated that signet-ring cell cancers did not have functional E-cadherin protein, while normal intact glands did (Fig. 4) . No patient had any evidence of lymph node metastases despite the fact that the average number of lymph nodes examined on each specimen was 24 and the range was 18 to 40. No patient received any other treatment (radiation or chemotherapy).
All patients have remained free of tumor at 1-year follow-up. Each is able to eat normally with more frequent meals and has occasional intermittent episodes of fullness and some discomfort. These episodes appear to be related to amount of food consumed. Each patient has lost weight following the surgery, with a mean weight loss of 40 pounds (range, 20 -60 pounds). Each patient maintains normal activities and has returned to work. Each patient states that he or she would undergo the operation again.
All 4 of the female patients have been evaluated by clinical breast examination, and by one or more rounds of annual screening with mammography and breast MRI. All had normal mammograms, but 2 had abnormalities noted on breast MRI. To date, 1 patient has undergone 2 excisional breast biopsies, both showing atypical lobular hyperplasia. Immunohistochemical staining with antibodies against Ecadherin confirmed lobular differentiation of the atypical periductal cells. All 4 women are currently taking tamoxifen with a goal of breast cancer risk reduction.
DISCUSSION
Familial diffuse gastric cancer is a disease with autosomal dominant inheritance in which lethal gastric cancer develops at a young age. 1, 2, 5, 9 Germline truncating mutations in the E-cadherin gene (CDH1) have been identified in a number of families with HDGC. 1, 2, 16, 24, 27, 28 In this study, we have identified a family with HDGC and a truncating CDH1 mutation at codon 1003. This mutation has been seen in 2 other families and, from haplotype analysis, appears to be a recurrent mutation resulting from independent events. 1 Whether phenotypic information or penetrance of cancer risk may be associated with particular mutations, such as codon 1003, remains unknown, as CDH1 mutations in HDGC families have been found throughout the gene, with very few recurrent mutations. Six members of this family with the germline CDH1 mutation have prospectively undergone total gastrectomy on an IRB approved protocol. Gastrectomy was done despite the fact that each person had completely normal extensive evaluation of the stomach, including stool for guaiac, endoscopy with endoscopic ultrasound, high-magnification chromoendoscopy, PET, CT, and multiple random stomach biopsies. In addition, 4 other CDH1 mutation carriers in this family have undergone prophylactic gastrectomies at other institutions, off study ( Fig. 1) . By report, all 4 also had signet-ring cell gastric cancer identified pathologically, although the extent of their preoperative screening workup is not known. One additional family member (individual "c" in Fig. 1 ) had a prophylactic gastrectomy over 30 years ago, prior to CDH1 testing, and was ultimately found not to carry the family mutation.
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Mutations in the E-Cadherin Gene A significant issue with HDGC, that limits screening methods to diagnose it early, is its diffuse multifocal infiltrative biology. 9, 22, 29, 30 It is usually not associated with mass lesions or ulcers. In fact, patients with the diffuse signet-ring cell type of gastric cancer commonly present with linitus plastica or diffuse involvement of the entire stomach. [31] [32] [33] Recently, other investigators have recommended the use of PET scan or chromoendoscopy directed biopsies in at-risk individuals to screen for early detection of cancer. 34, 35 Van Kouwen et al reported a single case in which a documented CDH1 carrier from a HDGC family had 2 abnormal foci identified by FDG-PET in the proximal and pyloric regions of the stomach, and following gastrectomy, signet-ring carcinoma was found in these and other areas. 26 Shaw et al have performed chromoendoscopy with both methylene blue and Congo red in 33 CDH1 carriers, and biopsied 56 abnormal appearing lesions. Twenty-three of these showed signet-ring cell carcinoma (10 patients), and subsequent prophylactic gastrectomies from some of these patients demonstrated that only lesions 4 to 10 mm were detected endoscopically, but not those Ͻ4mm. 35 Our data suggest that these screening procedures have low sensitivity for detecting early gastric cancer in patients with HDGC. In our series of 6 patients, PET scan, chromoendoscopy, and endoscopic ultrasound were negative in every patient despite the fact that each had invasive cancer. Indeed, the stomach and lymph nodes were grossly normal in appearance, and palpation in every patient suggesting that preoperative diagnostic and imaging studies will often fail to detect early cancers.
Another reason for recommending other screening procedures rather than total gastrectomy is the less than complete penetrance of gastric cancer in patients with CDH1 mutations, with most studies suggesting that 3 of 4 carriers of the CDH1 mutation will develop gastric cancer. 2, 23, 24 Indeed, in a previous report, 1 patient with the CDH1 mutation underwent total gastrectomy and was found not to have cancer. 1 However, in the current study, each patient with the mutation had multifocal invasive diffuse gastric cancer with pure signet-ring cell histology, and in our experience at Stanford with 2 additional HDGC families, 6 other CDH1 carriers undergoing prophylactic gastrectomy have had identified signet-ring cell carcinoma. Nevertheless, for those choosing not FIGURE 3. Invasive signet-ring cell carcinoma in prophylactic total gastrectomy specimens from 6 patients with hereditary diffuse gastric cancer and CDH1 E-cadherin gene mutations. A-F, Individual foci of signet-ring cell carcinoma in patients 1 to 6, respectively, from pedigree depicted in Figure 1 . Cancers were multifocal, predominantly superficial, and confined to the submucosa in all cases (hematoxylin and eosin stain).
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Annals of Surgery • Volume 245, Number 6, June 2007 to pursue a prophylactic gastrectomy at this time, we do recommend careful screening. Our current approach for individuals in known HDGC families is to recommend genetic counseling and testing for CDH1 carriage by the early 20s, and biannual chromoendoscopy and biopsies by the age of 25 or at least 10 years earlier than the youngest family member affected by cancer. Furthermore, for women with CDH1 mutations, we recommend a similar approach to screening as for other hereditary breast cancer syndromes, including annual mammography and breast MRI starting at the age of 25 years. 2 In this series of 6 consecutive patients, multifocal invasive diffuse gastric cancer with pure signet-ring cell histology was present in every instance and none had lymph node metastases. Therefore, this was not a prophylactic gastrectomy but a therapeutic one. The expected long-term 5-year survival of patients with presumably sporadic T1 , N0, M0 adenocarcinoma of the stomach is 78%. 36 In each of the patients diagnosed by the CDH1 mutation, the gastric cancer was stage 1a. This means that the cancer has invaded under the epithelium into the mucosa, but not into the submucosa or other tissues including lymph nodes. This pathology result is favorable, but approximately 20% of these patients may be at risk for recurrence. We are following these patients for gastric cancer recurrence with annual PET/CT, physical examination, routine laboratory, and tumor markers. However, although we have chosen to follow with PET/CT, it is not clearly indicated, but rather our preference. These patients are also undergoing upper gastrointestinal endoscopy every 2 years. We think that the prognosis of these patients may be better than predicted for sporadic gastric cancer, and we have not chosen to add adjuvant chemotherapy or radiation despite the proven benefit for stage II to IV gastric cancer patients. 37 Another potential drawback for "prophylactic" surgery for individuals with CDH1 mutations is the morbidity and mor-tality of total gastrectomy. 4, 38, 39 Certainly, the current study argues in favor of surgery as the immediate short-term morbidity and mortality was excellent in that no patient had any complications. The short hospital stay, no blood transfusion, large number of lymph nodes, and lack of morbidity make the current approach the method of choice. The expected deathrate with total gastrectomy is as high as 2% to 4%. 40 In a prophylactic gene-directed operation, death is clearly an unacceptable outcome. 41 The long-term complications of total gastrectomy include diarrhea, dumping, and weight loss. The expected incidence is nearly 100%. 2 Each patient in this study developed weight loss, and each reports intermittent eating difficulties. This will require additional monitoring before we are sure of the long-term adverse effects of total gastrectomy in this population. At present, no patient has developed recurrent gastric cancer or other tumors, and each appears to be functioning reasonably well as all have returned to a productive life.
We chose to perform an open total gastrectomy with D-2 lymph node dissection as part of this protocol. We did it with no morbidity and mortality, but only 6 patients were treated. Since no patients had lymph node metastases and the morbidity of D-2 lymph node dissection has been shown in previous studies 42 to be greater than routine gastrectomy, we do not recommend a D-2 lymph node dissection for these patients. We recommend removing the nodes along the left gastric artery and the greater omentum. Further, recent evidence from surgery for morbid obesity extrapolated to this condition supports the attempted use of laparoscopic total gastrectomy in patients with CDH1 mutations. Clearly, the entire stomach must be removed in every case as each patient had multiple diffuse sites of gastric cancer. However, if the stomach can be completely removed laparoscopically with similar low morbidity and mortality, it may improve the recovery and significantly reduce the pain and time to normal activity of the procedure.
Molecular biology and the genetic changes associated with the development of cancer have been able to change the way that we manage some cancer patients. 43 For example, the detection of a RET gene mutation in patients from kindreds with multiple endocrine neoplasia type 2A (MEN2A), familial medullary thyroid carcinoma (FMTC), or MEN2B mandates a total thyroidectomy because of the high penetrance of medullary thyroid carcinoma in these individuals. 44 -49 In MEN2A patients, the RET gene mutation allows the diagnosis of thyroid cancer prior to any clinical signs of the tumor. 44, 50 The thyroid glands appear absolutely normal, yet in situ MTC is commonly present on microscopic examination. Thus, the early diagnosis of inherited cancer through molecular techniques mandates that surgery be considered in the treatment of this disease. 24 It does not make sense to do all the standard diagnostic tests, including endoscopy with multiple biopsies, PET/CT, and endoscopic ultrasound, because none of those studies was able to detect gastric cancer that was already present in every case. Our recommendation is to proceed with total gastrectomy in gene carriers who are 5 years younger than the age of the youngest family member who developed gastric cancer. This study demonstrates a second example of an inherited cancer that is diagnosed by a gene mutation but cannot be detected at an early stage with current state-of-the-art screening methodologies mandating a potentially curative surgical procedure. Now, when individuals from families with HDGC have a CDH1 gene mutation, total gastrectomy is indicated. The current results and the literature 1,23 support this recommendation, as despite negative preoperative studies most patients have early invasive signetring cell gastric cancer. Further, exactly like the experience in familial MTC there is no curative treatment of gastric cancer other than early detection and total removal of the organ. The cure rate in patients with MTC diagnosed by RET gene mutations is nearly 100%, and we anticipate a similar cure rate in HDGC patients diagnosed by CDH1 mutation. This is another example of geneticists and genetic counselors, oncologists, gastroenterologists, radiologists, surgeons, and pathologists working together to turn an inherited lethal disease into one that is curable. In the future, we expect other molecular markers to provide early diagnosis and curative surgery.
